Metraipolis › archive › dc_072397dc4e4b

Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage — Europe PMC PMID:41544073

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41544073
DOI
10.1371/journal.pone.0340023
License (as archived)
solo-consultazione
Archived
2026-11-06T18:06:28.178Z
SHA-256 of the archived text
d61822c5b8ea1b30945f8560594c78aa6bffbed1999af6291de6d07057b681af
Stable URL of this page
https://metraipolis.com/documento/dc_072397dc4e4b

How to cite

Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage — Europe PMC PMID:41544073 — Europe PMC (en), https://europepmc.org/article/MED/41544073 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_072397dc4e4b (Metraipolis archive dc_072397dc4e4b, sha256 d61822c5b8ea1b30945f8560594c78aa6bffbed1999af6291de6d07057b681af)
BibTeX
@misc{dc072397dc4e4b,
  title = {Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage — Europe PMC PMID:41544073},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41544073},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_072397dc4e4b; sha256 d61822c5b8ea1b30945f8560594c78aa6bffbed1999af6291de6d07057b681af},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41544073. Agents can read the archived copy with the MCP tool read_document.